ÌÇÐÄvlog´«Ã½

Yersiniosis Diagnostics & Treatment Market Analysis

The Yersiniosis diagnostics and treatment market is expected to register a CAGR of 6.8% over the forecast period, 2022-2027.

The COVID-19 outbreak is a rare public health concern that has had a huge global impact on the market globally as hospital and healthcare services were severely curtailed due to social exclusion and the supply chain was hampered. The exceptional rise in coronavirus-infected patients, and limited access to alternate primary care services, sped up the decline in non-COVID-19-related diagnoses, such as Yersiniosis. The reported cases of Yersiniosis were fewer in 2020 than in 2019 due to the decrease in footfall in hospitals and clinics. For instance, according to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the reported cases of Yersiniosis in the European Union decreased in 2020 as compared to the previous year. However, with the decreasing COVID-19 cases and large-scale vaccination, the diagnosis of Yersiniosis is expected to increase and the studied market is anticipated to regain its potential over the forecast period.

Therefore, the Yersiniosis diagnostics and treatment market will impede around the world with the emergence of the COVID-19 pandemic, but it will have a positive impact on the decreasing cases of COVID-19. After the COVID-19's impact has diminished, the market in some regions will gradually demonstrate consistent growth.

The market is expected to grow due to the high prevalence of Yersiniosis in Northern Europe and countries in Central Europe and improved diagnostic techniques. According to the 2020 Surveillance Atlas of Infectious Diseases by the European Centre for Disease Prevention and Control, the overall notification rate of 1.7 per 100 000 population remained stable from 2015 to 2020 in the European Union. But the highest notification rates were found in countries of Northern and Central Europe. According to the same source, in 2020 the highest Incidence rate of 7.09 per 100 000 population was found in Denmark. Thus, the above increase in the prevalence of Yersiniosis in some regions may have a positive impact on the Yersniosis diagnosis market and treatment during the forecast period.

One of the major reasons for Yersiniosis's spread is the consumption of contaminated food. The symptoms of infected young children include fever, abdominal pain, and diarrhea. In May 2022, World Health Organization published that, children under 5 years of age carry 40% of the foodborne disease burden, with 125 000 deaths every year. This increase in foodborne diseases may indirectly have a positive impact on enteric bacterial infections like Yersiniosis. Thus, the increase in foodborne diseases may help the growth of the Yersiniosis diagnostics and treatment market in the studied period.

The advent of more advanced diagnostic technologies like realtime PCR, ELISA, and Luminex Immunoassay helps in the identification of enteropathogenic Yersinia species by differentiation of Yersinia enterocolitica and Yersinia pseudotuberculosis. These improved diagnosis methods help in Yersiniosis diagnostics and treatment market help to witness high growth over the forecast period. However, a lack of awareness in developing and underdeveloped countries on Yersiniosis disease, diagnosis, and treatment will impede the market.

Yersiniosis Diagnostics & Treatment Market Trends

This section covers the major market trends shaping the Yersiniosis Diagnostics & Treatment Market according to our research experts:

ELISA is Expected to Have a Major Share Over the Forecast Period

Yersiniosis Diagnostics & Treatment Industry Segmentation

As per the scope of the report, Yersiniosis is an infection caused most often by eating raw or undercooked pork contaminated with Yersinia enterocolitica bacteria. Yersinia enterocolitica has six biotypes, of which five are considered pathogenic in humans (biotypes 1B, 2, 3, 4, and 5). The Yersiniosis Diagnostics and Treatment Market are segmented by Bacterial Species (Yersinia enterocolitica, Yersinia pseudotuberculosis), Product Type (Diagnosis Technique and Therapeutics), Diagnosis Technique (Real-Time PCR, ELISA, Immunoassay, Protein Microarray, Stool Culture, and Other Diagnosis Technique), Therapeutics (Aminoglycosides, Sulfonamides, Cephalosporins, Fluoroquinolones, Tetracyclines, and Other Therapeutics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.